Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
Prostate cancer is the most common cancer in men and radical prostatectomy is the most
frequent treatment for this disease. Unfortunately, approximately 40% of patients will
develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation
after recurrence is successful in less than half of these men and most of those die from
their disease. Measures to prevent recurrence are an important research priority for prostate
cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is
routinely used to treat patients with metastases, but few clinical trials have examined if
adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research
oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of
ADT immediately after surgery will be safe and will significantly improve cancer outcomes.